Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

 Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Shots:

  • The company reports the availability of Amgevita, referencing Humira to treat 11 chronic inflammatory conditions in Canada
  • Amgevita is available as a prefilled syringe and a prefilled pen (SureClick autoinjector) with a broad range of pack sizes to support dosing for each indication and available in a citrate-free formulation. Amgevita is reimbursed on the public drug for all indications of Humira in British Columbia, Alberta, Ontario, Quebec, New Brunswick and Newfoundland
  • The approval was based on the clinical study that supports bio-similarity with the Humira and showed no clinical differences from the reference product

Click here to­ read full press release/ article | Ref: Amgen | Image: Amgen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post